Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| GLUE | PRESS-RELEASE | neutral | 2/10 | Monte Rosa Therapeutics granted inducement equity awards totaling 20,050 stock options and 4,400 RSUs to four new non-ex | Jun 2, 2026 |
| PRAX | PRESS-RELEASE | neutral | 1/10 | Praxis Precision Medicines granted 2,754 restricted stock units to 13 new non-executive employees under its 2024 Inducem | Jun 2, 2026 |
| PRQR | 6-K | neutral | 2/10 | ProQR Therapeutics filed a 6-K reporting the results of its 2026 annual general meeting of shareholders held on June 2, | Jun 2, 2026 |
| NRXP | PRESS-RELEASE | bearish | 6/10 | NRx Pharmaceuticals announced an underwritten public offering of common stock, with an option for underwriters to purcha | Jun 2, 2026 |
| FBRX | 8-K | neutral | 3/10 | Forte Biosciences filed an 8-K reporting the results of its 2026 annual meeting, where stockholders approved the amended | Jun 2, 2026 |
| HBIO | 8-K | neutral | 3/10 | Harvard Bioscience held its 2026 Annual Meeting on June 2, 2026, where stockholders approved an amendment to the Employe | Jun 2, 2026 |
| INMB | 8-K | bullish | 7/10 | INmune Bio reported statistically significant treatment effects on a white matter MRI biomarker (chi-separation) from th | Jun 2, 2026 |
| LEEEF | 8-K | bearish | 6/10 | Leef Brands Inc. is conducting a two-tranche private placement raising up to ~$4.5M total: (1) up to ~$1.5M in units (co | Jun 2, 2026 |
| PDSB | 8-K | bullish | 5/10 | PDS Biotechnology Corp received a Nasdaq notice on June 2, 2026 confirming it has regained compliance with the $1.00 min | Jun 2, 2026 |
| VCEL | 144 | neutral | 2/10 | Jonathan M. Hopper, an officer of Vericel Corp, filed a Form 144 on June 2, 2026, indicating intent to sell 4,375 shares | Jun 2, 2026 |
| QNTM | 6-K | bearish | 7/10 | Quantum BioPharma disclosed that the FDA placed its lead drug candidate Lucid-MS (for multiple sclerosis) on clinical ho | Jun 2, 2026 |
| DRUG | 6-K | neutral | 2/10 | Bright Minds Biosciences Inc. filed a Form 6-K with the SEC on June 2, 2026, providing notice of its Annual General Meet | Jun 2, 2026 |
| HYFT | 6-K | bullish | 6/10 | MindWalk reported preclinical dengue data showing that immunogens designed on a HYFT-computationally-predicted target el | Jun 2, 2026 |
| LEGN | PRESS-RELEASE | bullish | 7/10 | Legend Biotech announced promising Phase 1 data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy, showing 1 | Jun 2, 2026 |
| LEGN | 6-K | bullish | 7/10 | Legend Biotech announced initial Phase 1 data for LB2501, a first-in-class in vivo CD19/CD20 dual-targeting CAR-T therap | Jun 2, 2026 |
| CRDF | PRESS-RELEASE | bullish | 8/10 | Cardiff Oncology announced positive Phase 2 data for onvansertib in first-line RAS-mutated mCRC at ASCO 2026, showing a | Jun 2, 2026 |
| ONCY | 8-K | neutral | 2/10 | Oncolytics Biotech announced the appointment of Stephen Glover to its Board of Directors and the promotion of John McAdo | Jun 2, 2026 |
| SNSE | 10-K/A | neutral | 3/10 | Sensei Biotherapeutics filed Amendment No. 1 to its 2025 Form 10-K solely to revise Part I Item 1 (Business) in response | Jun 2, 2026 |
| MAIA | CLUSTER | bullish | 5/10 | Two insiders at MAIA Biotechnology purchased $103K in open-market shares, representing 0.13% of market cap. While cluste | Jun 2, 2026 |
| KZIA | 6-K | neutral | 3/10 | Kazia Therapeutics announced the appointment of James Levine as Chief Financial Officer, effective June 1, 2026. Mr. Lev | Jun 2, 2026 |
| SNSE | S-3/A | bearish | 6/10 | Sensei Biotherapeutics filed an S-3/A to register up to 24,868,028 shares of common stock for resale by selling stockhol | Jun 2, 2026 |
| ACHV | 8-K | neutral | 2/10 | Achieve Life Sciences appointed Jeff Farrow and Dr. Reid Waldman as directors effective May 29, 2026. Both receive stand | Jun 2, 2026 |
| KURA | PRESS-RELEASE | bullish | 6/10 | Kura Oncology announced publication in Blood of updated Phase 1a/b KOMET-007 data for ziftomenib + venetoclax + azacitid | Jun 2, 2026 |
| BIAFW | 8-K | neutral | 2/10 | bioAffinity Technologies announced via an 8-K that the Society for Advanced Bronchoscopy will host a webinar on June 16, | Jun 2, 2026 |
| SLS | 8-K | neutral | 3/10 | SELLAS Life Sciences disclosed it received approximately $28.7 million in warrant exercise proceeds during April and May | Jun 2, 2026 |
| CINGW | 8-K | bearish | 7/10 | Cingulate received a Complete Response Letter (CRL) from the FDA for its lead NDA, CTx-1301 (ADHD), citing only Chemistr | Jun 2, 2026 |
| CADL | PRESS-RELEASE | bullish | 8/10 | Candel Therapeutics announced publication of its pivotal Phase 3 trial results for aglatimagene (CAN-2409) in localized | Jun 2, 2026 |
| URGN | 8-K | neutral | 5/10 | UroGen Pharma settled patent litigation with Teva over Jelmyto (mitomycin) for pyelocalyceal solution. Under the settlem | Jun 2, 2026 |
| LNTH | PRESS-RELEASE | neutral | 4/10 | Lantheus announced that an image from its LNTH-2513 (18F-GP1) PET/CT trial for deep vein thrombosis (DVT) was awarded SN | Jun 2, 2026 |
| IMTX | 6-K | neutral | 3/10 | Immatics N.V. filed a 6-K on June 2, 2026, convening its Annual General Meeting (AGM) scheduled for June 18, 2026. The A | Jun 2, 2026 |